For example, sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of glucose-lowering agents for the treatment of type 2 diabetes by selectively inhibiting renal glucose reabsorption and increasing urinary glucose excretion. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.